← Search & browse all drugs

etilamfetamine

A08AA06

Forms & Strengths

Historically available in various oral formulations (tablets, capsules) in select European jurisdictions
Currently classified as an illicit designer drug and controlled substance with no standardized pharmaceutical preparations

Adult Dosing

No approved therapeutic dosing guidelines due to high abuse liability and withdrawal of clinical use
Historically studied or used at doses ranging from 10 mg to 30 mg orally for appetite suppression

Pediatric Dosing

Contraindicated and not recommended in pediatric populations due to severe cardiovascular and neuropsychiatric risks

Indications

Historically used as an anorectic agent for short-term management of exogenous obesity
Currently lacks any accepted medical indications and is regulated as a controlled substance

Mechanism of Action

Indirect sympathomimetic amine acting as a releaser of norepinephrine and dopamine
Promotes synaptic accumulation of biogenic amines to suppress appetite and stimulate the central nervous system

Contraindications

History of cardiovascular disease, severe hypertension, or advanced arteriosclerosis
Concomitant use with or within 14 days of monoamine oxidase inhibitors (MAOIs)
History of substance use disorder or drug abuse
Glaucoma, hyperthyroidism, and agitated states

Adverse Reactions

Tachycardia, palpitations, and elevated blood pressure
Insomnia, anxiety, restlessness, and tremor
Psychosis, hallucinations, and paranoia with chronic use or high doses
Dry mouth, nausea, and decreased appetite

Drug Interactions

Monoamine oxidase inhibitors (MAOIs): Risk of hypertensive crisis
Sympathomimetic agents: Potentiation of cardiovascular and central nervous system stimulation
Antihypertensive agents: Antagonism of the blood pressure-lowering effects
General anesthetics: Risk of severe cardiac arrhythmias

Curated Content: Needs Vetting Before Put to Clinical Use